Ethinyloestradiol-Levonorgestrel versus Low-Dose Spironolactone-Pioglitazone-Metformin (SPIOMET) for Adolescent Girls with Polycystic Ovary Syndrome: On-Treatment and Post-Treatment Observations

Trial Profile

Ethinyloestradiol-Levonorgestrel versus Low-Dose Spironolactone-Pioglitazone-Metformin (SPIOMET) for Adolescent Girls with Polycystic Ovary Syndrome: On-Treatment and Post-Treatment Observations

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Ethinylestradiol/levonorgestrel (Primary) ; Metformin; Pioglitazone; Spironolactone
  • Indications Hyperandrogenism; Hyperinsulinaemia; Polycystic ovary syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Apr 2017 Results presented at The 99th Annual Meeting of the Endocrine Society
    • 04 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top